Logo image of PDEX

PRO-DEX INC (PDEX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PDEX - US74265M2052 - Common Stock

37.72 USD
-0.76 (-1.98%)
Last: 1/2/2026, 8:00:01 PM
37.72 USD
0 (0%)
After Hours: 1/2/2026, 8:00:01 PM
Fundamental Rating

5

PDEX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. PDEX scores excellent on profitability, but there are some minor concerns on its financial health. PDEX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

PDEX had positive earnings in the past year.
In the past year PDEX has reported a negative cash flow from operations.
PDEX had positive earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: PDEX reported negative operating cash flow in multiple years.
PDEX Yearly Net Income VS EBIT VS OCF VS FCFPDEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M

1.2 Ratios

PDEX has a better Return On Assets (17.41%) than 98.39% of its industry peers.
The Return On Equity of PDEX (26.96%) is better than 97.85% of its industry peers.
PDEX's Return On Invested Capital of 16.51% is amongst the best of the industry. PDEX outperforms 96.24% of its industry peers.
PDEX had an Average Return On Invested Capital over the past 3 years of 14.16%. This is significantly above the industry average of 8.84%.
The last Return On Invested Capital (16.51%) for PDEX is above the 3 year average (14.16%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 17.41%
ROE 26.96%
ROIC 16.51%
ROA(3y)10.79%
ROA(5y)11.4%
ROE(3y)17.93%
ROE(5y)20.5%
ROIC(3y)14.16%
ROIC(5y)12.68%
PDEX Yearly ROA, ROE, ROICPDEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

PDEX has a better Profit Margin (15.94%) than 91.94% of its industry peers.
In the last couple of years the Profit Margin of PDEX has declined.
PDEX has a better Operating Margin (15.36%) than 83.87% of its industry peers.
In the last couple of years the Operating Margin of PDEX has declined.
PDEX's Gross Margin of 28.09% is on the low side compared to the rest of the industry. PDEX is outperformed by 76.88% of its industry peers.
In the last couple of years the Gross Margin of PDEX has declined.
Industry RankSector Rank
OM 15.36%
PM (TTM) 15.94%
GM 28.09%
OM growth 3Y9.36%
OM growth 5Y-4.56%
PM growth 3Y7.44%
PM growth 5Y-5.13%
GM growth 3Y-2.11%
GM growth 5Y-4.93%
PDEX Yearly Profit, Operating, Gross MarginsPDEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

6

2. Health

2.1 Basic Checks

PDEX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
PDEX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for PDEX has been reduced compared to 5 years ago.
Compared to 1 year ago, PDEX has a worse debt to assets ratio.
PDEX Yearly Shares OutstandingPDEX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
PDEX Yearly Total Debt VS Total AssetsPDEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

PDEX has an Altman-Z score of 6.53. This indicates that PDEX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PDEX (6.53) is better than 83.87% of its industry peers.
PDEX has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
PDEX has a Debt to Equity ratio (0.21) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 6.53
ROIC/WACC1.66
WACC9.95%
PDEX Yearly LT Debt VS Equity VS FCFPDEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 3.73 indicates that PDEX has no problem at all paying its short term obligations.
PDEX has a better Current ratio (3.73) than 65.59% of its industry peers.
PDEX has a Quick Ratio of 2.14. This indicates that PDEX is financially healthy and has no problem in meeting its short term obligations.
PDEX has a Quick ratio (2.14) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.73
Quick Ratio 2.14
PDEX Yearly Current Assets VS Current LiabilitesPDEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 107.14% over the past year.
Measured over the past years, PDEX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.96% on average per year.
The Revenue has grown by 23.65% in the past year. This is a very strong growth!
PDEX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.84% yearly.
EPS 1Y (TTM)107.14%
EPS 3Y35.1%
EPS 5Y10.96%
EPS Q2Q%86.67%
Revenue 1Y (TTM)23.65%
Revenue growth 3Y16.57%
Revenue growth 5Y13.84%
Sales Q2Q%24.43%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.48%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PDEX Yearly Revenue VS EstimatesPDEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
PDEX Yearly EPS VS EstimatesPDEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2 2.5

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 11.82, which indicates a very decent valuation of PDEX.
91.94% of the companies in the same industry are more expensive than PDEX, based on the Price/Earnings ratio.
PDEX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.60.
With a Price/Forward Earnings ratio of 15.54, PDEX is valued correctly.
Based on the Price/Forward Earnings ratio, PDEX is valued cheaply inside the industry as 86.02% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.23, PDEX is valued a bit cheaper.
Industry RankSector Rank
PE 11.82
Fwd PE 15.54
PDEX Price Earnings VS Forward Price EarningsPDEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PDEX is valued cheaply inside the industry as 90.86% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.81
PDEX Per share dataPDEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

The decent profitability rating of PDEX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.08
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

PDEX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

PRO-DEX INC

NASDAQ:PDEX (1/2/2026, 8:00:01 PM)

After market: 37.72 0 (0%)

37.72

-0.76 (-1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)01-29 2026-01-29
Inst Owners31.88%
Inst Owner Change-3.05%
Ins Owners36.03%
Ins Owner Change1.64%
Market Cap122.97M
Revenue(TTM)70.23M
Net Income(TTM)11.19M
Analysts82.86
Price Target57.12 (51.43%)
Short Float %10.16%
Short Ratio4.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)74.8%
Min EPS beat(2)-24.91%
Max EPS beat(2)174.51%
EPS beat(4)3
Avg EPS beat(4)69.51%
Min EPS beat(4)-24.91%
Max EPS beat(4)174.51%
EPS beat(8)5
Avg EPS beat(8)44.11%
EPS beat(12)7
Avg EPS beat(12)20.2%
EPS beat(16)8
Avg EPS beat(16)16.17%
Revenue beat(2)1
Avg Revenue beat(2)7.28%
Min Revenue beat(2)-4.18%
Max Revenue beat(2)18.74%
Revenue beat(4)2
Avg Revenue beat(4)7.58%
Min Revenue beat(4)-4.18%
Max Revenue beat(4)19.3%
Revenue beat(8)6
Avg Revenue beat(8)12.93%
Revenue beat(12)9
Avg Revenue beat(12)11.32%
Revenue beat(16)12
Avg Revenue beat(16)11.48%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 11.82
Fwd PE 15.54
P/S 1.75
P/FCF N/A
P/OCF N/A
P/B 2.96
P/tB 2.96
EV/EBITDA 9.81
EPS(TTM)3.19
EY8.46%
EPS(NY)2.43
Fwd EY6.44%
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS21.54
BVpS12.73
TBVpS12.73
PEG (NY)N/A
PEG (5Y)1.08
Graham Number30.23
Profitability
Industry RankSector Rank
ROA 17.41%
ROE 26.96%
ROCE 21.27%
ROIC 16.51%
ROICexc 20.85%
ROICexgc 20.86%
OM 15.36%
PM (TTM) 15.94%
GM 28.09%
FCFM N/A
ROA(3y)10.79%
ROA(5y)11.4%
ROE(3y)17.93%
ROE(5y)20.5%
ROIC(3y)14.16%
ROIC(5y)12.68%
ROICexc(3y)16.6%
ROICexc(5y)14.6%
ROICexgc(3y)16.62%
ROICexgc(5y)14.63%
ROCE(3y)18.25%
ROCE(5y)16.34%
ROICexgc growth 3Y23.73%
ROICexgc growth 5Y-8.41%
ROICexc growth 3Y23.84%
ROICexc growth 5Y-8.25%
OM growth 3Y9.36%
OM growth 5Y-4.56%
PM growth 3Y7.44%
PM growth 5Y-5.13%
GM growth 3Y-2.11%
GM growth 5Y-4.93%
F-Score6
Asset Turnover1.09
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA 0.72
Cap/Depr 73.12%
Cap/Sales 1.3%
Interest Coverage 12.57
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.73
Quick Ratio 2.14
Altman-Z 6.53
F-Score6
WACC9.95%
ROIC/WACC1.66
Cap/Depr(3y)99.37%
Cap/Depr(5y)344.26%
Cap/Sales(3y)1.93%
Cap/Sales(5y)6.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)107.14%
EPS 3Y35.1%
EPS 5Y10.96%
EPS Q2Q%86.67%
EPS Next Y-4.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.65%
Revenue growth 3Y16.57%
Revenue growth 5Y13.84%
Sales Q2Q%24.43%
Revenue Next Year4.48%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.16%
EBIT growth 3Y27.48%
EBIT growth 5Y8.65%
EBIT Next Year10.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-206.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.63%
OCF growth 3YN/A
OCF growth 5YN/A

PRO-DEX INC / PDEX FAQ

Can you provide the ChartMill fundamental rating for PRO-DEX INC?

ChartMill assigns a fundamental rating of 5 / 10 to PDEX.


What is the valuation status for PDEX stock?

ChartMill assigns a valuation rating of 5 / 10 to PRO-DEX INC (PDEX). This can be considered as Fairly Valued.


Can you provide the profitability details for PRO-DEX INC?

PRO-DEX INC (PDEX) has a profitability rating of 7 / 10.


What is the financial health of PRO-DEX INC (PDEX) stock?

The financial health rating of PRO-DEX INC (PDEX) is 6 / 10.


What is the expected EPS growth for PRO-DEX INC (PDEX) stock?

The Earnings per Share (EPS) of PRO-DEX INC (PDEX) is expected to decline by -4.43% in the next year.